全文获取类型
收费全文 | 1288919篇 |
免费 | 83566篇 |
国内免费 | 2996篇 |
专业分类
耳鼻咽喉 | 15505篇 |
儿科学 | 44514篇 |
妇产科学 | 33584篇 |
基础医学 | 179404篇 |
口腔科学 | 31483篇 |
临床医学 | 112959篇 |
内科学 | 247062篇 |
皮肤病学 | 25011篇 |
神经病学 | 106071篇 |
特种医学 | 51122篇 |
外国民族医学 | 305篇 |
外科学 | 197208篇 |
综合类 | 27824篇 |
一般理论 | 536篇 |
预防医学 | 105020篇 |
眼科学 | 28201篇 |
药学 | 89774篇 |
4篇 | |
中国医学 | 2826篇 |
肿瘤学 | 77068篇 |
出版年
2019年 | 9337篇 |
2018年 | 35373篇 |
2017年 | 27941篇 |
2016年 | 32276篇 |
2015年 | 13870篇 |
2014年 | 18707篇 |
2013年 | 27801篇 |
2012年 | 43432篇 |
2011年 | 60393篇 |
2010年 | 41663篇 |
2009年 | 33477篇 |
2008年 | 56803篇 |
2007年 | 62408篇 |
2006年 | 38794篇 |
2005年 | 39796篇 |
2004年 | 40173篇 |
2003年 | 40152篇 |
2002年 | 36651篇 |
2001年 | 48396篇 |
2000年 | 49404篇 |
1999年 | 41369篇 |
1998年 | 11978篇 |
1997年 | 10803篇 |
1996年 | 10412篇 |
1995年 | 10731篇 |
1994年 | 9999篇 |
1993年 | 9280篇 |
1992年 | 32957篇 |
1991年 | 32199篇 |
1990年 | 31669篇 |
1989年 | 30457篇 |
1988年 | 27728篇 |
1987年 | 27899篇 |
1986年 | 25921篇 |
1985年 | 25176篇 |
1984年 | 18965篇 |
1983年 | 16016篇 |
1982年 | 9991篇 |
1981年 | 8889篇 |
1979年 | 17269篇 |
1978年 | 12554篇 |
1977年 | 10620篇 |
1976年 | 10019篇 |
1975年 | 10387篇 |
1974年 | 12585篇 |
1973年 | 12082篇 |
1972年 | 11041篇 |
1971年 | 10233篇 |
1970年 | 9516篇 |
1969年 | 8888篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Nicholas B. Abt Lauren E. Miller Tara E. Mokhtari Derrick T. Lin Jeremy D. Richmon Daniel G. Deschler Mark A. Varvares Sidharth V. Puram 《American journal of otolaryngology》2021,42(6):103070
ObjectiveTo determine prognostic factors and survival patterns for different treatment modalities for nasal cavity (NC) and paranasal sinus (PS) mucosal melanoma (MM).MethodsPatients from 1973 to 2013 were analyzed using the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier method and multivariable cox proportional hazard modeling were used for survival analyses.ResultsOf 928 cases of mucosal melanoma (NC = 632, PS = 302), increasing age (Hazard Ratio [HR]:1.05/year, p < 0.001), T4 tumors (HR: 1.81, p = 0.02), N1 status (HR: 6.61, p < 0.001), and PS disease (HR: 1.50, p < 0.001) were associated with worse survival. Median survival length was lower for PS versus NC (16 versus 26 months, p < 0.001). Surgery and surgery + radiation therapy (RT) improved survival over non-treatment or RT alone (p < 0.001). Adding RT to surgery did not yield a survival difference compared with surgery alone (p = 0.43). Five-year survival rates for surgery and surgery + RT were similar, at 27.7% and 25.1% (p = 0.43).ConclusionSurgery increased survival significantly over RT alone. RT following surgical resection did not improve survival. 相似文献
2.
3.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
4.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
5.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
6.
7.
8.
Polyakova E. B. Sabirzyanov D. R. Prozorova N. A. Foteeva A. B. 《Pharmaceutical Chemistry Journal》2022,55(10):1119-1125
Pharmaceutical Chemistry Journal - Metformin hydrochloride is widely used to treat diabetes mellitus. This review presents its physical and chemical properties and discusses methods of analysis... 相似文献
9.
Huttunen Kristiina M. Terasaki Tetsuya Urtti Arto Montaser Ahmed B. Uchida Yasuo 《Pharmaceutical research》2022,39(7):1363-1392
Pharmaceutical Research - One of the major reasons why central nervous system (CNS)-drug development has been challenging in the past, is the barriers that prevent substances entering from the... 相似文献
10.
Khadka J. Ratcliffe J. Hutchinson C. Cleland J. Mulhern B. Lancsar E. Milte R. 《Quality of life research》2022,31(9):2849-2865
Quality of Life Research - To evaluate the construct (convergent and known group) validity of the Quality-of-Life-Aged Care Consumer (QOL-ACC), an older-person-specific quality-of-life measure... 相似文献